Download PDF
Semin Reprod Med
DOI: 10.1055/s-0044-1790225
Review Article

Impact of Antiphospholipid Syndrome on Reproductive Outcomes: Current Insights and Management Approaches

Lauren He
1   Division of Rheumatology, University of Michigan, Ann Arbor, Michigan
,
Catherine Sims 
1   Division of Rheumatology, University of Michigan, Ann Arbor, Michigan
2   Division of Rheumatology, Duke University, Durham, North Carolina
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Antiphospholipid syndrome (APS) is a disease characterized by the presence of antiphospholipid (aPL) antibodies, thrombosis, and obstetric complications. While patients with APS can have successful pregnancies, many important considerations exist. APS can also cooccur with other systemic autoimmune diseases which can affect pregnancy, particularly systemic lupus erythematosus. This article reviews specific considerations for pregnancy and reproductive health in patients with APS. Similar to other autoimmune diseases, stable or quiescent disease and planning with a rheumatologist and obstetrician prior to conception are vital components of a successful pregnancy. Pregnancy management for patients with aPL antibodies or diagnosis of APS with aspirin and/or anticoagulation depending on disease profile is discussed, as well as the effects of physiologic changes during pregnancy in maternal and fetal outcomes for this population. Given the reproductive span lasts beyond conception through delivery, we include discussions on safe contraception options, the use of assistive reproductive technology, pregnancy termination, menopause, and male fertility. While APS is a relatively rare condition, the effects this disease can have on maternal and fetal outcomes even with available therapies demonstrates the need for more high-quality, evidence-based research.

Keywords

antiphospholipid syndrome - pregnancy - reproduction


Publication History

Article published online:
24 October 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
    CrossrefPubMedSearch in Google Scholar
  • 2 Barbhaiya M, Zuily S, Naden R. et al; ACR/EULAR APS Classification Criteria Collaborators. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol 2023; 75 (10) 1687-1702
    CrossrefPubMedSearch in Google Scholar
  • 3 Litvinova E, Darnige L, Kirilovsky A, Burnel Y, de Luna G, Dragon-Durey MA. Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol 2018; 9: 2971
    CrossrefPubMedSearch in Google Scholar
  • 4 Duarte-García A, Pham MM, Crowson CS. et al. The epidemiology of antiphospholipid syndrome: a population-based study. [published correction appears in Arthritis Rheumatol. 2020 Apr;72(4):597] Arthritis Rheumatol 2019; 71 (09) 1545-1552
    CrossrefPubMedSearch in Google Scholar
  • 5 Erkan D, Derksen R, Levy R. et al. Antiphospholipid Syndrome Clinical Research Task Force report. Lupus 2011; 20 (02) 219-224
    CrossrefPubMedSearch in Google Scholar
  • 6 Sammaritano LR, Bermas BL, Chakravarty EE. et al. 2020 American College of Rheumatology Guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken) 2020; 72 (04) 461-488
    CrossrefPubMedSearch in Google Scholar
  • 7 Centers for Disease Control and Prevention. Recommended Vaccines for Adults. CDC.gov. Published 2023. Accessed August 16, 2024 at: https://www.cdc.gov/vaccines/adults/rec-vac/index.html
    PubMed
  • 8 Bass AR, Chakravarty E, Akl EA. et al. 2022 American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken) 2023; 75 (03) 449-464
    CrossrefPubMedSearch in Google Scholar
  • 9 Karakaş Ö, Erden A, Armağan B. et al. Evaluation of patients with antiphospholipid syndrome subsequently COVID-19 vaccinations: a retrospective cohort study. Int J Rheum Dis 2023; 26 (02) 292-297
    CrossrefPubMedSearch in Google Scholar
  • 10 Pan H, Tang Z, Teng J. et al. COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study. Rheumatology (Oxford) 2023; 62 (02) 829-834
    CrossrefPubMedSearch in Google Scholar
  • 11 Kato Y, Morita T, Kumanogoh A. Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases. Inflamm Regen 2023; 43 (01) 1
    CrossrefPubMedSearch in Google Scholar
  • 12 Signorelli F, Balbi GGM, Aikawa NE. et al. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus 2022; 31 (08) 974-984
    CrossrefPubMedSearch in Google Scholar
  • 13 World Health Organization. Family planning/Contraception. Published September 5, 2023. Accessed August 16, 2024 at: https://www.who.int/news-room/fact-sheets/detail/family-planning-contraception
    PubMed
  • 14 Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348 (9033): 977-980
    CrossrefPubMedSearch in Google Scholar
  • 15 Stam-Slob MC, Lambalk CB, van de Ree MA. Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ 2015; 351: h4847
    CrossrefPubMedSearch in Google Scholar
  • 16 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception 1998; 57 (05) 315-324
    CrossrefPubMedSearch in Google Scholar
  • 17 van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30 (11) 2297-2300
    CrossrefPubMedSearch in Google Scholar
  • 18 Conard J, Plu-Bureau G, Bahi N, Horellou MH, Pelissier C, Thalabard JC. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004; 70 (06) 437-441
    CrossrefPubMedSearch in Google Scholar
  • 19 Killian M, van Mens TE. Risk of thrombosis, pregnancy morbidity or death in antiphospholipid syndrome. Front Cardiovasc Med 2022; 9: 852777
    CrossrefPubMedSearch in Google Scholar
  • 20 Sammaritano LR. Which hormones and contraception for women with APS? Exogenous hormone use in women with APS. Curr Rheumatol Rep 2021; 23 (06) 44
    CrossrefPubMedSearch in Google Scholar
  • 21 Kim JW, Jung JY, Kim HA, Yang JI, Kwak DW, Suh CH. Lupus low disease activity state achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus. J Rheumatol 2021; 48 (05) 707-716
    CrossrefPubMedSearch in Google Scholar
  • 22 Buyon JP, Kim MY, Guerra MM. et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med 2015; 163 (03) 153-163
    CrossrefPubMedSearch in Google Scholar
  • 23 Andreoli L, Bertsias GK, Agmon-Levin N. et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017; 76 (03) 476-485
    CrossrefPubMedSearch in Google Scholar
  • 24 Tektonidou MG, Andreoli L, Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78 (10) 1296-1304
    CrossrefPubMedSearch in Google Scholar
  • 25 Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril 1996; 66 (04) 540-546
    CrossrefPubMedSearch in Google Scholar
  • 26 Lynch A, Marlar R, Murphy J. et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 1994; 120 (06) 470-475
    CrossrefPubMedSearch in Google Scholar
  • 27 Schreiber K, Hunt BJ. Pregnancy and antiphospholipid syndrome. Semin Thromb Hemost 2016; 42 (07) 780-788
    Thieme ConnectPubMedSearch in Google Scholar
  • 28 Wuu J, Hellerstein S, Lipworth L. et al. Correlates of pregnancy oestrogen, progesterone and sex hormone-binding globulin in the USA and China. Eur J Cancer Prev 2002; 11 (03) 283-293
    CrossrefPubMedSearch in Google Scholar
  • 29 Battinelli EM, Marshall A, Connors JM. The role of thrombophilia in pregnancy. Thrombosis 2013; 2013: 516420
    CrossrefPubMedSearch in Google Scholar
  • 30 James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol 2005; 193 (01) 216-219
    CrossrefPubMedSearch in Google Scholar
  • 31 Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton III LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143 (10) 697-706
    CrossrefPubMedSearch in Google Scholar
  • 32 Dhital R, Baer RJ, Bandoli G. et al. Maternal cardiovascular events in autoimmune rheumatic diseases and antiphospholipid syndrome pregnancies. Am J Obstet Gynecol MFM 2024; 6 (04) 101319
    CrossrefPubMedSearch in Google Scholar
  • 33 Abe K, Kuklina EV, Hooper WC, Callaghan WM. Venous thromboembolism as a cause of severe maternal morbidity and mortality in the United States. Semin Perinatol 2019; 43 (04) 200-204
    CrossrefPubMedSearch in Google Scholar
  • 34 Silver RM. Catastrophic antiphospholipid syndrome and pregnancy. Semin Perinatol 2018; 42 (01) 26-32
    CrossrefPubMedSearch in Google Scholar
  • 35 Cervera R, Piette JC, Font J. et al; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46 (04) 1019-1027
    CrossrefPubMedSearch in Google Scholar
  • 36 Rodríguez-Pintó I, Moitinho M, Santacreu I. et al; CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies). Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev 2016; 15 (12) 1120-1124
    CrossrefPubMedSearch in Google Scholar
  • 37 Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. [published correction appears in Circ Res. 2020 Jan 3;126(1):e8] Circ Res 2019; 124 (07) 1094-1112
    CrossrefPubMedSearch in Google Scholar
  • 38 Saleem FR, Chandru S, Biswas M. Evaluation of total LDH and its isoenzymes as markers in preeclampsia. J Med Biochem 2020; 39 (03) 392-398
    PubMedSearch in Google Scholar
  • 39 Cebesoy FB, Balat O, Dikensoy E, Kalayci H, Ibar Y. CA-125 and CRP are elevated in preeclampsia. Hypertens Pregnancy 2009; 28 (02) 201-211
    CrossrefPubMedSearch in Google Scholar
  • 40 Zhao X, Frempong ST, Duan T. Uric acid levels in gestational hypertensive women predict preeclampsia and outcome of small-for-gestational-age infants. J Matern Fetal Neonatal Med 2021; 34 (17) 2825-2831
    CrossrefPubMedSearch in Google Scholar
  • 41 Karrar SA, Hong PL. Preeclampsia. In: StatPearls. Treasure Island, FL: StatPearls Publishing; February 13, 2023
  • 42 Savignano C, Rinaldi C, De Angelis V. Pregnancy associated thrombotic thrombocytopenic purpura: practical issues for patient management. Transfus Apher Sci 2015; 53 (03) 262-268
    CrossrefPubMedSearch in Google Scholar
  • 43 Chiasakul T, Cuker A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematology (Am Soc Hematol Educ Program) 2018; 2018 (01) 530-538
    CrossrefPubMedSearch in Google Scholar
  • 44 Rimaitis K, Grauslyte L, Zavackiene A, Baliuliene V, Nadisauskiene R, Macas A. Diagnosis of HELLP syndrome: a 10-year survey in a perinatology centre. Int J Environ Res Public Health 2019; 16 (01) 109
    CrossrefPubMedSearch in Google Scholar
  • 45 Uckan K, Sahin HG. Serum amyloid A, procalcitonin, highly sensitive C reactive protein and tumor necrosis factor alpha levels and acute inflammatory response in patients with hemolysis, elevated liver enzymes, low platelet count (HELLP) and eclampsia. J Obstet Gynaecol Res 2018; 44 (03) 440-447
    CrossrefPubMedSearch in Google Scholar
  • 46 Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A review. BMC Pregnancy Childbirth 2009; 9: 8
    CrossrefPubMedSearch in Google Scholar
  • 47 Rai RS, Regan L, Clifford K. et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995; 10 (08) 2001-2005
    CrossrefPubMedSearch in Google Scholar
  • 48 Lockshin MD, Kim M, Laskin CA. et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64 (07) 2311-2318
    CrossrefPubMedSearch in Google Scholar
  • 49 Ruffatti A, Tonello M, Visentin MS. et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 2011; 50 (09) 1684-1689
    CrossrefPubMedSearch in Google Scholar
  • 50 Clark EA, Silver RM, Branch DW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?. Curr Rheumatol Rep 2007; 9 (03) 219-225
    CrossrefPubMedSearch in Google Scholar
  • 51 Rand JH, Wu XX, Guller S, Scher J, Andree HA, Lockwood CJ. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol 1997; 177 (04) 918-923
    CrossrefPubMedSearch in Google Scholar
  • 52 Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7 (06) 330-339
    CrossrefPubMedSearch in Google Scholar
  • 53 Hackelöer M, Schmidt L, Verlohren S. New advances in prediction and surveillance of preeclampsia: role of machine learning approaches and remote monitoring. Arch Gynecol Obstet 2023; 308 (06) 1663-1677
    CrossrefPubMedSearch in Google Scholar
  • 54 Brito-Zerón P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015; 11 (05) 301-312
    CrossrefPubMedSearch in Google Scholar
  • 55 Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin use to prevent preeclampsia and related morbidity and mortality: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2021; 326 (12) 1192-1206
    CrossrefPubMedSearch in Google Scholar
  • 56 Rolnik DL, Wright D, Poon LC. et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377 (07) 613-622
    CrossrefPubMedSearch in Google Scholar
  • 57 Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 2010; 49 (02) 281-288
    CrossrefPubMedSearch in Google Scholar
  • 58 Walfisch A, Koren G. The “warfarin window” in pregnancy: the importance of half-life. J Obstet Gynaecol Can 2010; 32 (10) 988-989
    CrossrefPubMedSearch in Google Scholar
  • 59 Clowse MEB, Eudy AM, Balevic S. et al. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med 2022; 9 (01) e000651
    CrossrefPubMedSearch in Google Scholar
  • 60 Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta MA, Cuadrado MJ. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol 2016; 214 (02) 273.e1-273.e8
    CrossrefPubMedSearch in Google Scholar
  • 61 Pengo V, Ruffatti A, Legnani C. et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8 (02) 237-242
    CrossrefPubMedSearch in Google Scholar
  • 62 Xu Q, Dai L, Chen HQ. et al. Specific changes and clinical significance of plasma D-dimer during pregnancy and puerperium: a prospective study. BMC Pregnancy Childbirth 2023; 23 (01) 248
    CrossrefPubMedSearch in Google Scholar
  • 63 Bao SH, Sheng SL, Liao H, Zhou Q, Frempong ST, Tu WY. Use of D-dimer measurement to guide anticoagulant treatment in recurrent pregnancy loss associated with antiphospholipid syndrome. Am J Reprod Immunol 2017; 78 (06) 10
    CrossrefPubMedSearch in Google Scholar
  • 64 Bao SH, Frempong ST, Ruan JL. D-dimer assay may guide LMWH treatment in repeated biochemical pregnancy losses in women with positive antiphospholipid antibody. Clin Lab 2020; 66 (03) 10
    PubMedSearch in Google Scholar
  • 65 Rocha APC, Carmo RL, Melo RFQ, Vilela DN, Leles-Filho OS, Costa-Silva L. Imaging evaluation of nonobstetric conditions during pregnancy: what every radiologist should know. Radiol Bras 2020; 53 (03) 185-194
    CrossrefPubMedSearch in Google Scholar
  • 66 Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MS. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 2014; 370 (14) 1307-1315
    CrossrefPubMedSearch in Google Scholar
  • 67 Newborn and Infant Breastfeeding. Accessed August 16, 2024 at: www.aap.org https://www.aap.org/en/patient-care/newborn-and-infant-nutrition/newborn-and-infant-breastfeeding/
    PubMed
  • 68 Drugs and Lactation Database (LactMed). National Library of Medicine (US); 2006. Accessed August 16, 2024 at: https://www.ncbi.nlm.nih.gov/books/NBK501922/
    PubMed
  • 69 Branch DW, Lim MY. How I diagnose and treat antiphospholipid syndrome in pregnancy. Blood 2024; 143 (09) 757-768
    CrossrefPubMedSearch in Google Scholar
  • 70 Postpartum Depression. www.acog/org. Published December 2021. Accessed August 16, 2024 at: https://www.acog.org/womens-health/faqs/postpartum-depression
    PubMed
  • 71 Mughal S, Azhar Y, Siddiqui W. Postpartum Depression. In: StatPearls. Treasure Island, FL: StatPearls Publishing; October 7, 2022
  • 72 Vinet E, Scott S, Ehrmann Feldman D. et al. Increased risk of postpartum depression in . SLE pregnancies. [abstract] Arthritis Rheumatol 2016; 68 (10) 2487-2491
    PubMedSearch in Google Scholar
  • 73 Carp HJ, Shoenfeld Y. Anti-phospholipid antibodies and infertility. Clin Rev Allergy Immunol 2007; 32 (02) 159-161
    CrossrefPubMedSearch in Google Scholar
  • 74 Rodrigues VO, Soligo AGES, Pannain GD. Antiphospholipid antibody syndrome and infertility. Rev Bras Ginecol Obstet 2019; 41 (10) 621-627
    Thieme ConnectPubMedSearch in Google Scholar
  • 75 Buckingham KL, Chamley LW. A critical assessment of the role of antiphospholipid antibodies in infertility. J Reprod Immunol 2009; 80 (1-2): 132-145
    CrossrefPubMedSearch in Google Scholar
  • 76 Huong DL, Wechsler B, Vauthier-Brouzes D. et al. Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles. Semin Arthritis Rheum 2002; 32 (03) 174-188
    CrossrefPubMedSearch in Google Scholar
  • 77 Lockshin MD, Guerra M, Salmon JE. Elective termination of pregnancy in autoimmune rheumatic diseases: experience from two databases. Arthritis Rheumatol 2020; 72 (08) 1325-1329
    CrossrefPubMedSearch in Google Scholar
  • 78 Lee JK, Zimrin AB, Sufrin C. Society of Family Planning clinical recommendations: management of individuals with bleeding or thrombotic disorders undergoing abortion. Contraception 2021; 104 (02) 119-127
    CrossrefPubMedSearch in Google Scholar
  • 79 Tschann M, Edelman A, Jensen J, Bednarek P, Kaneshiro B. Blood loss at the time of dilation and evacuation at 16 to 22 weeks of gestation in women using low molecular weight heparin: a case series. Contraception 2018; 97 (01) 54-56
    CrossrefPubMedSearch in Google Scholar
  • 80 Castillo-Martínez D, Rivera V, Mouneu-Ornelas N. et al. Levels of anti-Müllerian hormone in premenopausal women with the antiphospholipid syndrome and its association with the risk of clinical complications. Lupus 2019; 28 (03) 427-431
    CrossrefPubMedSearch in Google Scholar
  • 81 Vega M, Barad DH, Yu Y. et al. Anti-Mullerian hormone levels decline with the presence of antiphospholipid antibodies. Am J Reprod Immunol 2016; 76 (04) 333-337
    CrossrefPubMedSearch in Google Scholar
  • 82 Silva CA, Yamakami LY, Aikawa NE, Araujo DB, Carvalho JF, Bonfá E. Autoimmune primary ovarian insufficiency. Autoimmun Rev 2014; 13 (4-5): 427-430
    CrossrefPubMedSearch in Google Scholar
  • 83 Yang Y, Huang XX, Huo RX, Lin JY. Sexual health in women with Sjogren's syndrome: a review. Eur J Obstet Gynecol Reprod Biol 2023; 291: 1-9
    CrossrefPubMedSearch in Google Scholar
  • 84 Liang R, Xu H, Yao R. et al. A predictive model for premature atherosclerosis in systemic lupus erythematosus based on clinical characteristics. Clin Rheumatol 2024; 43 (05) 1541-1550
    CrossrefPubMedSearch in Google Scholar
  • 85 Chandrashekara S. Osteoporosis in rheumatology. Indian J Orthop 2023; 57 (Suppl. 01) 176-180
    CrossrefPubMedSearch in Google Scholar
  • 86 Grygiel-Górniak B, Limphaibool N, Puszczewicz M. Clinical implications of systemic lupus erythematosus without and with antiphospholipid syndrome in peri- and postmenopausal age. Przegl Menopauz 2018; 17 (02) 86-90
    PubMedSearch in Google Scholar
  • 87 Desai MK, Brinton RD. Autoimmune disease in women: endocrine transition and risk across the lifespan. Front Endocrinol (Lausanne) 2019; 10: 265
    CrossrefPubMedSearch in Google Scholar
  • 88 Karvonen-Gutierrez CA, Leis A. Impact of menopause on women with systemic lupus erythematosus. Maturitas 2021; 154: 25-30
    CrossrefPubMedSearch in Google Scholar
  • 89 ACOG Practice Bulletin No. ACOG Practice Bulletin No. 141: management of menopausal symptoms. [published correction appears in Obstet Gynecol. 2016 Jan;127(1):166] [published correction appears in Obstet Gynecol. 2018 Mar;131(3):604] Obstet Gynecol 2014; 123 (01) 202-216
    CrossrefPubMedSearch in Google Scholar
  • 90 Witten T, Staszkiewicz J, Gold L. et al. Nonhormonal pharmacotherapies for the treatment of postmenopausal vasomotor symptoms. Cureus 2024; 16 (01) e52467
    PubMedSearch in Google Scholar
  • 91 Truglia S, Capozzi A, Mancuso S. et al. Relationship between gender differences and clinical outcome in patients with the antiphospholipid syndrome. Front Immunol 2022; 13: 932181
    CrossrefPubMedSearch in Google Scholar
  • 92 Smart E, Lopes F, Rice S. et al. Chemotherapy drugs cyclophosphamide, cisplatin and doxorubicin induce germ cell loss in an in vitro model of the prepubertal testis. Sci Rep 2018; 8 (01) 1773
    CrossrefPubMedSearch in Google Scholar
  • 93 Wyrobek AJ, Schmid TE, Marchetti F. Relative susceptibilities of male germ cells to genetic defects induced by cancer chemotherapies. J Natl Cancer Inst Monogr 2005; (34) 31-35
    CrossrefPubMedSearch in Google Scholar
  • 94 Soares PM, Borba EF, Bonfa E, Hallak J, Corrêa AL, Silva CA. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum 2007; 56 (07) 2352-2361
    CrossrefPubMedSearch in Google Scholar